Loading stock data…
GDRX
$2.56-0.09 (-3.21%)
Market OpenUpdated 2:59 PM EDT
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GoodRx Holdings, Inc. in the Healthcare sector is trading at $2.56. Wall Street consensus targets $3.18 (13 analysts), implying a +24.0% move over the next 12 months. The stock is currently near its 52-week low of $1.77, remaining 12.2% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +24.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $194.01M↓ | $194.78M↓ | $196.03M↓ | $203.07M | $202.97M |
| Gross Profit | $173.85M↓ | $177.32M↓ | $182.61M↓ | $189.72M | $189.61M |
| Operating Income | $14.01M↓ | $22.68M↑ | $14.62M↓ | $26.81M↑ | $23.38M |
| Net Income | $1.17M↓ | $5.42M↑ | $1.12M↓ | $12.84M↑ | $11.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that prov...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.30%
Volume
Today's trading volume
650,674
Recent News
GoodRx Holdings, Inc. (GDRX) Strengthens Recurring Revenue Base with Companion
GoodRx (NASDAQ:GDRX) is one of the top penny stocks to buy in investors’ stock portfolio. On May 27, GoodRx (NASDAQ:GDRX) affirmed its commitment to offering free and low-cost generic medications to the public. The company launched GoodRx Companion, a new $14.99-a-month subscription service that helps consumers save on routine healthcare costs. The service combines lower […]
1 Small-Cap Stock with Competitive Advantages and 2 We Ignore
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
3 Penny Stocks With Market Caps Over $100M To Watch
The market is up 1.2% over the last week, and in the past year, it has climbed an impressive 27%, with earnings expected to grow by 17% per annum. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present significant opportunities when built on solid financials. We've identified three penny stocks that demonstrate financial strength and potential for growth, offering investors a chance to uncover hidden value in quality...
How The Shifting Story For GoodRx (GDRX) Is Reshaping Analyst Views And Valuation
GoodRx Holdings is back in focus after a fair value estimate was raised to US$3.18 from US$2.82, putting fresh attention on where the stock might fit in your watchlist. Some analysts have moved price targets toward US$4 while others have pulled them down into the US$2 to US$3 range, reflecting very different reads on recent guidance and the business mix. Keep reading to see what is driving that split view and how you can follow the evolving narrative around GoodRx. Analyst Price Targets don't...
3 Reasons Retirees Should Reconsider Enrolling in a Standalone Medicare Drug Plan in 2026
You turn 65, sign up for Medicare, and a wall of mail arrives pushing standalone Part D drug plans. The default move for decades has been to pick one and forget it. For 2026, that default deserves a fresh look. The Inflation Reduction Act fully kicks in this year, premiums and surcharges shift, and bundled ... 3 Reasons Retirees Should Reconsider Enrolling in a Standalone Medicare Drug Plan in 2026